Cargando…
Effects of tolvaptan add-on therapy in patients with acute heart failure: meta-analysis on randomised controlled trials
OBJECTIVES: Treating acute decompensated heartfailure (ADHF) for improving congestion with diuretics may cause worsening renal function (WRF), but the clinical efficacy of tolvaptan add-on therapy on reducing WRF in ADHF patients is inconsistent. This analysis is to evaluate the effects of tolvaptan...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6501975/ https://www.ncbi.nlm.nih.gov/pubmed/31048435 http://dx.doi.org/10.1136/bmjopen-2018-025537 |
_version_ | 1783416177102422016 |
---|---|
author | Ma, Guang Ma, Xixi Wang, Guoliang Teng, Wei Hui, Xuezhi |
author_facet | Ma, Guang Ma, Xixi Wang, Guoliang Teng, Wei Hui, Xuezhi |
author_sort | Ma, Guang |
collection | PubMed |
description | OBJECTIVES: Treating acute decompensated heartfailure (ADHF) for improving congestion with diuretics may cause worsening renal function (WRF), but the clinical efficacy of tolvaptan add-on therapy on reducing WRF in ADHF patients is inconsistent. This analysis is to evaluate the effects of tolvaptan add-on therapy on reducing WRF in ADHF patients. METHODS: Meta-analysis of randomised trials of tolvaptan add-on therapy on reducing WRF in ADHF patients. The MEDLINE, Embase and Cochrane Central Register of Controlled Trials databases were searched for relevant articles from their inception to 31 October, 2017. Two reviewers filtrated the documents on WRF, short-term all-cause mortality, body weight decreased, elevated sodium level for calculating pooled relatives risks, weighted mean difference and associated 95% CIs. We used fixed-effects or random-effects models according to I(2) statistics. ACHIEVEMENTS: Seven random controlled trials with 937 patients were included for analysis. Compared with the control, tolvaptan add-on therapy did not improve incidence of worsening renal function (RR 0.78, 95% CI 0.48 to 1.26, p=0.31, I(2)=66%) and short-term all-cause mortality (RR 0.85, 95% CI 0.47 to 1.56, p=0.61, I(2)=0%). On subgroup analyses, there was a suggestion of possible effect modification by dose of tolvaptan, in which benefit was observed in low-dose (≤15 mg/day) group (RR 0.48, 95% CI 0.23 to 1.02, p=0.05, I(2)=54%), but not with high-dose (30 mg) group (RR 1.33, 95% CI 0.99 to 1.78, p=0.05, I(2)=0%). However, tolvaptan add-on therapy reduced body weight in 2 days (standardised mean difference −0.49, 95% CI −0.64 to −0.34, p<0.00001, I(2)=0%), increased sodium level (mean difference 1.56, 95% CI 0.04 to 3.07, p=0.04, I(2)=0%). CONCLUSION: The result suggests that comparing with the standard diuretic therapy, tolvaptan add-on therapy did not reduce the incidence of WRF and short-term mortality, however, it can decrease body weight and increase the sodium level in patients who are with ADHF. Further researches are still required for confirmation. |
format | Online Article Text |
id | pubmed-6501975 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-65019752019-05-21 Effects of tolvaptan add-on therapy in patients with acute heart failure: meta-analysis on randomised controlled trials Ma, Guang Ma, Xixi Wang, Guoliang Teng, Wei Hui, Xuezhi BMJ Open Cardiovascular Medicine OBJECTIVES: Treating acute decompensated heartfailure (ADHF) for improving congestion with diuretics may cause worsening renal function (WRF), but the clinical efficacy of tolvaptan add-on therapy on reducing WRF in ADHF patients is inconsistent. This analysis is to evaluate the effects of tolvaptan add-on therapy on reducing WRF in ADHF patients. METHODS: Meta-analysis of randomised trials of tolvaptan add-on therapy on reducing WRF in ADHF patients. The MEDLINE, Embase and Cochrane Central Register of Controlled Trials databases were searched for relevant articles from their inception to 31 October, 2017. Two reviewers filtrated the documents on WRF, short-term all-cause mortality, body weight decreased, elevated sodium level for calculating pooled relatives risks, weighted mean difference and associated 95% CIs. We used fixed-effects or random-effects models according to I(2) statistics. ACHIEVEMENTS: Seven random controlled trials with 937 patients were included for analysis. Compared with the control, tolvaptan add-on therapy did not improve incidence of worsening renal function (RR 0.78, 95% CI 0.48 to 1.26, p=0.31, I(2)=66%) and short-term all-cause mortality (RR 0.85, 95% CI 0.47 to 1.56, p=0.61, I(2)=0%). On subgroup analyses, there was a suggestion of possible effect modification by dose of tolvaptan, in which benefit was observed in low-dose (≤15 mg/day) group (RR 0.48, 95% CI 0.23 to 1.02, p=0.05, I(2)=54%), but not with high-dose (30 mg) group (RR 1.33, 95% CI 0.99 to 1.78, p=0.05, I(2)=0%). However, tolvaptan add-on therapy reduced body weight in 2 days (standardised mean difference −0.49, 95% CI −0.64 to −0.34, p<0.00001, I(2)=0%), increased sodium level (mean difference 1.56, 95% CI 0.04 to 3.07, p=0.04, I(2)=0%). CONCLUSION: The result suggests that comparing with the standard diuretic therapy, tolvaptan add-on therapy did not reduce the incidence of WRF and short-term mortality, however, it can decrease body weight and increase the sodium level in patients who are with ADHF. Further researches are still required for confirmation. BMJ Publishing Group 2019-05-01 /pmc/articles/PMC6501975/ /pubmed/31048435 http://dx.doi.org/10.1136/bmjopen-2018-025537 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Cardiovascular Medicine Ma, Guang Ma, Xixi Wang, Guoliang Teng, Wei Hui, Xuezhi Effects of tolvaptan add-on therapy in patients with acute heart failure: meta-analysis on randomised controlled trials |
title | Effects of tolvaptan add-on therapy in patients with acute heart failure: meta-analysis on randomised controlled trials |
title_full | Effects of tolvaptan add-on therapy in patients with acute heart failure: meta-analysis on randomised controlled trials |
title_fullStr | Effects of tolvaptan add-on therapy in patients with acute heart failure: meta-analysis on randomised controlled trials |
title_full_unstemmed | Effects of tolvaptan add-on therapy in patients with acute heart failure: meta-analysis on randomised controlled trials |
title_short | Effects of tolvaptan add-on therapy in patients with acute heart failure: meta-analysis on randomised controlled trials |
title_sort | effects of tolvaptan add-on therapy in patients with acute heart failure: meta-analysis on randomised controlled trials |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6501975/ https://www.ncbi.nlm.nih.gov/pubmed/31048435 http://dx.doi.org/10.1136/bmjopen-2018-025537 |
work_keys_str_mv | AT maguang effectsoftolvaptanaddontherapyinpatientswithacuteheartfailuremetaanalysisonrandomisedcontrolledtrials AT maxixi effectsoftolvaptanaddontherapyinpatientswithacuteheartfailuremetaanalysisonrandomisedcontrolledtrials AT wangguoliang effectsoftolvaptanaddontherapyinpatientswithacuteheartfailuremetaanalysisonrandomisedcontrolledtrials AT tengwei effectsoftolvaptanaddontherapyinpatientswithacuteheartfailuremetaanalysisonrandomisedcontrolledtrials AT huixuezhi effectsoftolvaptanaddontherapyinpatientswithacuteheartfailuremetaanalysisonrandomisedcontrolledtrials |